Dance Momsaired for nine seasons on Lifetime, and during that time, it produced a crop of memorable young dancers, like Lilliana Ketchman, aka Lilly K. Many of those young dancers, like Jojo Siwa and ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

HUNTSVILLE, Ala. (WAFF) - During a press conference held on Tuesday, pharmaceutical giant Eli Lilly announced that they will construct a $6 billion state-of-the-art pharmaceutical manufacturing plant ...

Shares of French biotech Abivax (ABVX) climbed in Paris on Wednesday, in a move Reuters attributed to market speculation about a potential takeover bid from weight-loss drugmaker Eli Lilly (LLY). The ...

Eli Lilly has unveiled the location of the third of its four large-scale manufacturing facilities that it plans to build in the U.S. The drugmaker has selected Huntsville, Alabama, as the site of a $6 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

Eli Lilly LLY-0.47%decrease; red down pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

SHANGHAI, Dec 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with type 2 diabetes, the ...

Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...